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GENERAL COMMENTS
The manuscript would benefit from citation of updated literature. One example is the comment in the Introduction that there is just one published study supporting a role for local consolidative therapy in patients presenting with metastatic NSCLC. A second randomised phase II trial, which also closed prematurely, has now been published [Iyengar P, JAMA Oncol. 2017 Sep 24:e173501. doi: 10.1001 /jamaoncol.2017 .
Some data can be updated. The reference to the SABR-COMET (NCT01446744) states that it is ongoing, whereas this study completed accrual in 2016.
The authors may which to clarify the use of somewhat restrictive study exclusion criteria , which assumes that only the use of radiation in this patients population is of clinical interest. However, it could be argued that the scientific question is one of whether the use of one or more consolidative treatments in this setting is beneficial. 
VERSION 1 -AUTHOR RESPONSE
Editors comments:
• After your abstract, please include an article summary' section consisting of the heading: 'Strengths and limitations of this study', and containing up to five short bullet points, no longer than one sentence each, that relate specifically to the methods of the study reported.
o Added (5 bullet points). Page 3
• Along with your revised manuscript, please provide a completed copy of the SPIRIT checklist (http://www.spirit-statement.org/). Please remember to include the relevant page number(s) from the manuscript next to each reporting item or state 'n/a' next to items that are not applicable to your study. • The authors may which to clarify the use of somewhat restrictive study exclusion criteria, which assumes that only the use of radiation in this patients population is of clinical interest. However, it could be argued that the scientific question is one of whether the use of one or more consolidative treatments in this setting is beneficial. o
We agree that it is correct that the results are likely applicable to other ablative therapies. However, patients with oligometastatic disease are a fairly diverse group in terms of sites and volume of disease therefore the trial design attempts to reduce other known variables as far as possible.
• One example of the above is the following exclusion Criteria: One or more metastases previously treated with alternative ablative treatment, e.g. RFA or Surgery. COMMENT: In clinical practice, an excisional biopsy may be performed in order to obtain sufficient tissue. Study accrual can only be improved if such patients who have at least 2 untreated metastases after an excision rem ain eligible o This point is well made and the trial management group are considering amending the protocol to allow excision biopsy. To date, this has not been a common reason for preventing recruitment. Furthermore, whilst various suggestions might be reasonable they are not necessarily relevant to whether the protocol should or should not be published.
• Another exclusion criteria is "Metastasis in sites where normal radiotherapy constraints cannot be met". COMMENT: In addition to the previous point, some centers may lack the expertise to confidently treat adrenal and liver metastases by means of SBRT, and the same centers may have expertise to perform a laparascopic excision of an adrenal metastasis, or RFA. o Again, this point is correct but the trial is designed to prevent a hotch potch of treatments in order to allow truly meaningful conclusions to be drawn from the results. The question here is not how to manage these patients but how to run a clinical trial.
• Please clarify exclusion criteria 14: Stage III disease even with extensive nodal disease o Clarification added. Page 11. The point is to ensure that only true stage IV NSCLC Is included and not stage III with a node that needs to be treated separately.
Reviewer: 2 Reviewer Name: Andrea Riccardo Filippi Institution and Country: University of Torino, Italy Please state any competing interests or state 'None declared': None declared The Authors should be congratulated for the design of such an important study in the field of metastatic NSCLC. The protocol is very well described, the endpoints are clear and the methodology is sound. Phase III data in this setting would be extremely useful for all clinicians.
Only 2 suggestions:
• at the time of my review, another phase II study on oligometastatic NSCLC has been published, by Iyengar P et al (JAMA Oncol 2017): it would be nice to also cite this study in the introduction. 
